1. Signal Transduction Pathways in Human Diseases Ron Bose, MD PhD Biochemistry and Molecular Cell Biology Programs Washington University School of Medicine Molecular Cell Biology Lecture. Oct 29, 2013

2. Introduction Pathways 1.Receptor Tyrosine Kinase 2.G-Protein signaling 3.Cyclic AMP and other Second Messenger Pathways 4.Nuclear Hormone Receptors 5.Cytokine receptors and JAK- STAT pathway Human Diseases Cancer Heart Disease Blood Pressure Kidney Diseases Pain and Pain relief

3. ErbB1 HER1 EGFR ErbB2 HER2 Neu ErbB3 HER3 ErbB4 HER4 I II III IV I II III IV I II III IV I II III IV Extracellular Cytoplasmic Transmembrane Kinase Domain N C N N C C C-terminal tail Zahnow, C.A., Expert Rev Mol Med. 2006 The EGFR family of Receptor Tyrosine Kinases { EGFRHer2/neuHer3Her4 Kinase Domain Inactive

4. from Marmor, Skaria, and Yarden 2004 ErbB Receptor Homo- or Heterodimerization

5. Her2/neu and Breast Cancer Her2 first identified as an oncogene from a carcinogen-induced rat brain tumor model. Her2 is gene amplified in about 25% of human breast cancers. Overexpression of Her2 in the mammary gland of transgenic mice causes breast cancer. Herceptin, a monoclonal antibody to Her2/neu, effectively treats Her2 gene amplified human breast cancer.

6. Her2/neu and Breast Cancer 1987 – Southern blots of genomic DNA from breast cancer patients shows Her2 gene amplification. –Sample 3 & 4: normal level –Sample 1 & 2: 2-5 x normal –Sample 6 & 26: >5 x normal –Sample 18: > 20 x normal Correlation between Her2 gene copy number and patient survival Slamon, et al., Science 1987 100% Time (months) Patient Survival 80% 60% 40% 20% 0%

7. Her2/neu and Breast Cancer Transgenic mice bearing the MMTV-Her2/neu construct develop breast cancer in all 5 pairs of mouse mammary glands. Tumor formation with Her2 in this tg model is more rapid than with the Myc oncogene. Muller et al., Cell 1988

8. Drugs to Target Receptor Tyrosine Kinases HER2 EGFR HER2 HomodimerHeterodimer Extracellular domain Tyrosine- kinase domains Monoclonal Antibodies ATP-mimetic Tyrosine Kinase Inhibitors

9. ErbB2 Cho et al. (2003) Nature Herceptin Franklin et al. (2004) Cancer Cell ErbB2Pertuzumab Therapeutic Antibodies Target Her2

10. Successful treating Her2 amplified Breast Cancer The combination of chemotherapy (AC  T) plus Herceptin markedly improves patient survival as compared to chemotherapy alone. Treatment of women with Herceptin has saved THOUSANDS of lives. New England Journal of Medicine 2005

11. Alterations of ErbB receptors in Cancer Overexpression/Gene Amplification Her2/neu - 25% of breast cancers, rarer in gastric and ovarian cancers. EGFR – many cancers including lung, breast, GI, ovarian, brain Mutations EGFR del E746-A750 EGFR L858R Both found in Lung cancer cases from Non-smokers. These cancers respond very well to Gefitinib (an anti- EGFR tyrosine kinase inhibitor).

12. Normal Lung Lung Cancer Prior to Treatment Marked Shrinkage of Cancer and improved lung aeration with Gefitinib.

13. Chronic Myeloid Leukemia (CML) and the Philadelphia Chromosome CML is diagnosed in 5,000 new patients each year in the US. A classic chromosomal rearrangement between chromosomes 9 and 22, named the Philadelphia chromosome, defines CML. This 9;22 translocation produces a fusion protein between the ABL tyrosine kinase and the BCR gene.

14. Chronic Myeloid Leukemia (CML) and BCR-ABL The BCR-ABL fusion protein activates several signaling pathways. Introduction of BCR-ABL gene in mice causes myeloid leukemias. Druker, Blood 2008

15. Abl can be inhibited with tyrosine kinase inhibitors. –Imatinib (Gleevec) –Dasatinib –Nilotinib Tyrosine kinase inhibitors have revolutionized the treatment of CML, reducing the death rate to only 270 deaths in the U.S. in 2011 (about 5% of incidence rate). Crystal structure of ABL tyrosine kinase with Imatinib (orange) bound. Chronic Myeloid Leukemia (CML) and BCR-ABL Druker, Blood 2008 and Schindler et al., Science 2000.

16. Targeting MAPK pathway in Cancer (C) Ras -GTP Raf (MAPKKK) MEK (MAPKK) Erk 1 & 2 (MAPK) Figure 6.12 The Biology of Cancer (© Garland Science 2007)

17. Targeting MAPK pathway in Cancer (C) Ras -GTP Raf (MAPKKK) MEK (MAPKK) Erk 1 & 2 (MAPK) Figure 6.12 The Biology of Cancer (© Garland Science 2007) T T Raf inhibitors MEK inhibitors

18. Targeting the PI 3-kinase/Akt pathway From Engelman, Luo, and Cantley, Nature Reviews Genetics 2006 AKT T PI3-Kinase inhibitors AKT inhibitor

19. Nuclear Hormone Receptors Nuclear hormone receptors bind ligands like steroids, thyroid hormone, retinoids, etc. They have DNA binding and hormone binding domains. Ligand binding causes transcriptional de-repression or activation.

20. The RARα Nuclear Hormone Receptor in Acute Promyelocytic Leukemia (APL) APL has a characteristic translocation 15;17 that forms the PML-RARα fusion protein. Retinoic Acid (RA) binding converts PML-RARα from a transcriptional repressor to a transcriptional activator. All-trans retinoic acid (ATRA) has made APL the most treatable and best prognosis form of adult acute leukemia. PML Retinoic Acid Binding DNA Binding Retinoic Acid Receptor α ATRA

21. G-Protein Coupled Receptors in Melanomas Metabotropic glutamate receptors (mGluR) are GPCR’s. mGluR1 or mGluR5 transgenic mice develop melanomas. Other GPCR’s implicated in cancer: –Chemokine receptors: CXCR2 and CXCR4 –Endothelin receptors Marin and Chen, J. Mol Med 2004

22. Signaling in Heart and Kidney Diseases  -Adrenergic signaling via GPCR’s 2.Renin-Angiotensin signaling via the Angiotensin II receptor 3.Erythropoietin signaling in anemia of chronic renal disease.

23. Cyclic AMP and GPCR signaling Cyclic AMP

24. Adrenergic Receptors bind Adrenaline/Epinephrine Glycosylation There are also  2 and  3 receptors.

25.  -Adrenergic Receptors stimulate cAMP production GsGs GsGs Adenylate Cyclase cAMPATP Protein Kinase A (PKA)

26. Physiologic Effects of  -Adrenergic Signaling 1.Heart – increased heart rate and contractility 2.Vascular - Dilation of the coronary arteries and arteries to skeletal muscles. 3.Dilation of the airways in the lung Commonly used medications:  -Blockers: control heart rate and blood pressure. Albuterol – The most common medicine for asthma. It is a  2 adrenergic agonist.

27. Downregulation/Desensitization of  -Adrenergic Receptor McDonald and Lefkowitz,Cell Signaling 2001

28. GPCR signaling Controls Blood Pressure via the Renin-Angiotensin System Angiotensinogen Angiotensin I Angiotensin II Renin (kidney) ACE (lung) (Angiotensin Converting Enzyme) Angiotensin II Receptor (GPCR) T ACE inhibitors T Angiotensin Receptor Blockers Common Blood Pressure Medicines

29. GPCR signaling Controls Blood Pressure via the Renin-Angiotensin System Timmermanns, Pharm Review 1993

30. Other Second Messengers Cyclic GMP IP 3 Small Lipids like: Diacylglycerol Ceramide

31. Cytokine Receptors activate the JAK-STAT pathway Nucleus STAT5 DNA Cytokine receptor JAK tyrosine kinase (a cytoplasmic tyr kinase) JAK STAT5 STAT transcription factors shuttle from cytoplasm to nucleus

32. Erythropoietin (EPO) binds to a Cytokine Receptor Nucleus STAT5 DNA JAK2 Tyr Kinase EPO receptor Munugalavadla and Kapur, Reviews in Onc-Hem, 2005

33. EPO Deficiency causes Anemia of Chronic Kidney Disease Chronic kidney disease causes a fall in EPO secretion and this results in decreased red blood cell production (i.e.- anemia). Therefore patients with chronic kidney disease are given recombinant EPO to prevent anemia. Kidney Bone Marrow Increased Red Blood Cell Production EPO

34. "Signal Transduction is a Pain” 1.Pain is a complex process. 2.Signal transduction pathways play a key role in it. 3.The 2 most commonly used classes of pain medications are: –Anti-inflammatory –Opiates Nakahata, Pharmacology & Therapeutics 2008

35. Anti-Inflammatory Medicines inhibit Thromboxane Synthesis Aspirin Ibuprofen Cyclooxygenase (COX) Inhibitors TXA 2 Nakahata, Pharmacology & Therapeutics 2008

36. Opiate Receptors are GPCR’s Morphine and related drugs are opiates and are commonly used pain medications. The major opiate receptors (δ, µ, and κ) are G-protein coupled receptors. The endogenous ligands for opiate receptors are peptide hormones like enkephalin, endorphins, and dynorphin. Brunton et al., Goodman & Gilman, The Pharmacological Basis of Therapeutics, 12 th Ed., 2011 Leu-enkephalin

37. Opiate Receptors are GPCR’s Opiate receptors can homo- and heterodimerize. Additionally, cross-talk between different GPCR’s occurs. A common side effect of morphine is itching. Itching is mediated by cross-talk between an alternately spliced µ opiate receptor (MOR1D) and the GRPR protein. Miyamoto et al., Cell 2011, Liu et al., Cell 2011

38. Summary 1.Signaling pathways play central roles in cell functioning and in human physiology. 2.Altered signaling pathways cause or contribute to human diseases. 3.Many drugs that are given to people directly affect signal transduction pathways.